This review summarizes recent advances in the development of HRV 3C protease inhibitors for the treatment of the common cold.
Answers are grounded in this paper and cite their sources.
Advances in HRV 3C protease inhibitor design remain preclinical; leaves open clinical efficacy for common cold treatment.
The human rhinoviruses (HRVs) are the most significant cause of the common cold. Important advances in the development of novel, broad spectrum antirhinoviral agents have recently been made by inhibiting the function of virally encoded enzymes essential for viral replication. This article summarises the most recent developments in the design of HRV 3C protease inhibitors which are intended for use as broad spectrum antirhinoviral therapeutic agents.
No takes yet. Share an insight, caveat, or question.
Peter S. Dragovich (2001) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: